Scale Events
+00:00 GMT
Sign in or Join the community to continue

Daphne Koller: AI-Driven Drug Discovery Using Digital Biology

Posted Oct 24, 2022 | Views 1.7K
# TransformX 2022
# Keynote
# AI in Healthcare
Share
speaker
avatar
Daphne Koller
CEO & Founder @ insitro

Daphne Koller is CEO and Founder of insitro, a machine learning-driven drug discovery and development company. Daphne is also co-founder of Engageli, was the Rajeev Motwani Professor of Computer Science at Stanford University, where she served on the faculty for 18 years, the co-CEO and President of Coursera, and the Chief Computing Officer of Calico Labs. She is the author of over 300 refereed publications appearing in venues such as Science, Cell, and Nature Genetics. Daphne was recognized as one of TIME Magazine’s 100 most influential people in 2012. She received the MacArthur Foundation Fellowship in 2004, the ACM Prize in Computing in 2008, and the IEEE CS Women of ENIAC Computer Pioneer award in 2022. She was inducted into the National Academy of Engineering in 2011 and elected a fellow of the American Association for Artificial Intelligence in 2004, the American Academy of Arts and Sciences in 2014, and the International Society of Computational Biology in 2017.

+ Read More
SUMMARY

Modern medicine has provided effective tools to treat some of humanity’s most significant and burdensome diseases. At the same time, it is becoming consistently more challenging and more expensive to develop new therapeutics. The drug development process involves multiple steps, each of which requires a complex and protracted experiment that often fails. Insitro CEO and Founder Daphne Koller believes that, for many of these phases, machine learning models can help predict the outcome of the experiments and that those models, while inevitably imperfect, can outperform predictions based on traditional heuristics.

In this keynote, Koller discusses how Insitro is bringing together high-quality data from human cohorts, while also developing cutting-edge methods in high-throughput biology and chemistry that can produce massive amounts of in vitro data relevant to human disease and therapeutic interventions.

Koller also covers how the data is then used to train machine learning models that make predictions about novel targets, coherent patient segments, and the clinical effect of molecules. Insitro’s ultimate goal is to develop a new approach to drug development that uses high-quality data and ML models to design novel, safe, and effective therapies that help more people faster, and at a lower cost.

Koller also co-founded Engageli and has served as the co-CEO and President of Coursera. She received the MacArthur Foundation Fellowship in 2004 and the ACM Prize in Computing in 2008, and was elected a fellow of the American Association for Artificial Intelligence in 2004, in addition to receiving many other honors and awards.

+ Read More

Watch More

31:05
Transforming Drug Discovery Using Machine Learning
Posted Oct 06, 2021 | Views 11.4K
# TransformX 2021
# Keynote